Victory Capital Management Inc. Grows Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Victory Capital Management Inc. increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 10.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 218,531 shares of the company’s stock after buying an additional 21,530 shares during the period. Victory Capital Management Inc. owned about 0.45% of Amphastar Pharmaceuticals worth $10,605,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AMPH. ProShare Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 6.9% in the 1st quarter. ProShare Advisors LLC now owns 10,973 shares of the company’s stock valued at $482,000 after purchasing an additional 708 shares in the last quarter. UniSuper Management Pty Ltd bought a new position in Amphastar Pharmaceuticals during the 1st quarter worth approximately $296,000. CANADA LIFE ASSURANCE Co grew its position in shares of Amphastar Pharmaceuticals by 29.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 39,930 shares of the company’s stock worth $1,752,000 after acquiring an additional 9,037 shares in the last quarter. Epoch Investment Partners Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 34.8% in the 1st quarter. Epoch Investment Partners Inc. now owns 798,462 shares of the company’s stock valued at $35,060,000 after acquiring an additional 205,932 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC raised its position in shares of Amphastar Pharmaceuticals by 35.1% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after acquiring an additional 29,182 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Rong Zhou sold 6,893 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total transaction of $336,929.84. Following the transaction, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at approximately $5,786,805.44. This trade represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,898,061.15. The trade was a 7.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,533 shares of company stock valued at $1,571,652 in the last quarter. Company insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on AMPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler lowered their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $44.09 on Thursday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The firm has a market capitalization of $2.12 billion, a PE ratio of 14.70, a P/E/G ratio of 0.89 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The business’s fifty day moving average price is $48.38 and its two-hundred day moving average price is $44.42.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.